Navigation Links
Array BioPharma Selects SciQuest to Automate Procurement and Enable Agile Drug Development
Date:4/29/2008

SciQuest Solution Manages Pharmaceutical Research Firm's Services and

Supplies Procurement

CARY, N.C., April 29 /PRNewswire/ -- SciQuest, Inc., the global leader in helping academic, healthcare and research-centric organizations realize the potential of strategic procurement, today announced that Array BioPharma Inc., a leading biopharmaceutical research and development company, has chosen SciQuest's eprocurement platform to automate procurement functions for each of its more than 250 scientists and researchers.

Array is focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, inflammatory diseases and pain. The company strives to achieve peak effectiveness by maintaining a sleek, flexible and rapid drug development process that avoids the slow development cycles characterized by other organizations in the pharmaceutical industry.

"SciQuest provides pharmaceutical researchers with an easy and efficient shopping platform to acquire and manage materials so they always have the items they need when they need them. As a result, researchers can remain focused on their work," said Stephen Wiehe, president and CEO of SciQuest. "With the capability to also accommodate services spend through outside vendors, SciQuest makes maverick spending a non-issue."

Array uses SciQuest's SelectSite(TM) and Requisition Manager solutions to help expedite the approval process of materials procurement, efficiently managing each approval and providing clear visibility into the progress of each request. SciQuest then integrates with Array's Oracle infrastructure to create purchase orders. In its most recent fiscal year, Array placed orders for more than 25,000 items and services through the SciQuest system. With SciQuest, Array has captured nearly 100 percent of the company's materials procurement through its procurement process.

"SciQuest helps research organizations succeed by enabling them to attain superior control and insight into their procurement spending," added Wiehe. "Our scalable architecture and on-demand deployment means that when growing companies like Array expand, SciQuest is there to meet their needs every step of the way."

About SciQuest

SciQuest is the global leader in helping academic, healthcare and research-centric organizations realize the potential of strategic procurement. The company's specialized knowledge, on-demand software, and service-first approach empower more than 100 of the best-known academic, pharmaceutical, biotechnology, research hospitals, and ambulatory surgical organizations to manage spend, drive ROI, and advance their critical missions.

SciQuest's strategic procurement solutions are strengthened by a deep understanding of the higher education, clinical and research environments combined with a broad supplier network for everything from lab equipment to office supplies to services. The company's intuitive, online shopping experience and diverse supplier offerings are proven to increase user and contract adoption. Through software-as-a-service (SaaS) deployment, organizations can quickly implement the right eprocurement solution, whether it's a robust shopping platform for existing eprocurement tools or to fully enable all aspects of purchasing from sourcing to settlement.

For more information about SciQuest, please visit http://www.sciquest.com or call 877-710-0413 in the U.S. or +44 1794 341182 in Europe.

SciQuest is a registered trademark of SciQuest, Inc. Other trademarks contained herein remain the property of their respective owners.

SciQuest media contact:

Ken Phillips

Davies Murphy Group

781-418-2437

kphillips@daviesmurphy.com


'/>"/>
SOURCE SciQuest, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. GenoLogics Geneus Achieves GeneChip-compatible(TM) Status with the Affymetrix GeneChip(R) Microarray Platform
2. IMPAC Medical Systems to Offer Revenue Cycle Inc.s Array of Oncology Products and Services to Customers
3. Worlds most complex silicon phased-array chip developed at UC-San Diego
4. Decision Biomarkers Awarded U.S. Patent for Protein Array Surface Chemistry
5. New Microbial Genome-to-Array Service
6. Jivan Awarded US Patent #7,340,349 for Splice Array Analysis
7. Immucor To Acquire BioArray Solutions Ltd.
8. Mobidiag Releases First Microarray Based Rapid Test for Herpesvirus Identification
9. Fred Hutchinson Cancer Research Center and NSB POSTECH, Inc. to Collaborate on Development of New Class of Proteomic Microarrays
10. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
11. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Brooklyn, NY (PRWEB) , ... June 24, 2016 , ... ... 15mm, machines such as the Cary 5000 and the 6000i models are higher end ... height is the height of the spectrophotometer’s light beam from the bottom of the ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
Breaking Biology Technology:
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
(Date:3/29/2016)... Florida , March 29, 2016 ... the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased ... in ink used in a variety of writing instruments, ... Buyers of originally created collectibles from athletes on LegacyXChange ... forensic analysis of the DNA. Bill ...
Breaking Biology News(10 mins):